SCHEMBL6851337

SCHEMBL6851337

Cc1ccc(C(=O)C2CCc3[nH]cnc3C2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
CYP2D6 P10635 1/20 0.47
HTR3A P46098 2/20 0.47
KCNH2 Q12809 2/20 0.47
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
SLC6A4 P31645 1/20 0.47
OPRK1 P41145 1/20 0.47
HTR2B P41595 1/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
HTT P42858 1/20 0.42
POLB P06746 2/20 0.39
MGLL Q99685 2/20 0.38
HSD11B1 P28845 1/20 0.38
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6851341 0.90 HTR3A (0.57) KMT2AMEN1CYP2D6HTR3AKCNH2
SCHEMBL6851005 0.87 HSD11B1 (0.42) HTR3AKCNH2ADRA2AADRA2BADRA2C
SCHEMBL6851425 0.87 MGLL (0.42) KMT2AMEN1HTR3AKCNH2ADRA2A
SCHEMBL6850905 0.86 HTR3A (0.48) HTR3AKCNH2ADRA2AADRA2BADRA2C
SCHEMBL7011484 0.86 NPC1 (0.50) KMT2AMEN1HTR3AKCNH2ADRA2A
SCHEMBL6853015 0.86 HTR3A (0.42) KMT2AMEN1HTR3AKCNH2ADRA2A
SCHEMBL6851123 0.86 HTR3A (0.42) KMT2AMEN1HTR3AKCNH2ADRA2A
SCHEMBL6852997 0.86 HTR3A (0.42) KMT2AMEN1HTR3AKCNH2ADRA2A
SCHEMBL6853002 0.86 HTR3A (0.42) KMT2AMEN1HTR3AKCNH2ADRA2A
SCHEMBL6850986 0.85 HTR3A (0.41) KMT2AMEN1CYP2D6HTR3AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756384-B2 TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. NOVO NORDISK A/S (DK) 2004-06-29 US disclosed
US-20030135056-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2003-07-17 US disclosed
EP-1268484-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 EP disclosed
US-6437147-B1 FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM NOVO NORDISK (DK) 2002-08-20 US disclosed
US-20020058659-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2002-05-16 US disclosed
WO-2001068652-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135056-A1 Imidazole compounds HRH3, HRH4, HRH2 KMT2A 300/4885MEN1 1139/4885CYP2D6 1085/4885
US-20020058659-A1 Imidazole compounds HRH3, HRH4, HRH2 KMT2A 300/4885MEN1 1139/4885CYP2D6 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.